Breast and Colorectal Cancer Screenings Rebound from Declines Post-COVID

Research led by American Cancer Society investigators shows that “both breast and colorectal cancer (CRC) screening rebounded from declines during the COVID-19 pandemic in the United States and surpassed screening estimates prior to the pandemic.”

At the same time, screening rates for cervical cancer are still below pre-pandemic levels, and CRC screening rates mostly improved in people with “higher socioeconomic status.” Jessica Star, the study’s lead author, said that the findings are “mostly encouraging” as they show a rebound after widespread disruptions in cancer screening in the U.S. She warned that the decline in cervical cancer screening is “troubling,” as it may lead to prevention and early-stage diagnoses continuing to drop.

Study results showed that “past-year breast and CRC screening in 2023 exceeded 2019 levels by 7% and 12% respectively because of sharp increases between 2021-2023 that offset declines or flat trends observed during the pandemic. Past-year cervical cancer screening in 2023 remained 14% below 2019 levels, with no change between 2021 and 2023.” Screening for both breast and CRC “only significantly improved in individuals with private or Medicare insurance.”

Star, the author, said that the decline in cervical cancer screening may reflect “longer-term declines in patient knowledge and clinicians recommending the test.” She also emphasized that “widening disparities in all cancer screenings by socioeconomic status” be addressed.